Skip to main content
Datesort ascending Press Release
18. Sep 2017 - 11:00 am IPF WORLD WEEK 2017: BOEHRINGER INGELHEIM HELPS HEALTH CARE PROFESSIONALS TO ‘LISTEN FOR THE SOUNDS OF IPF’   
18. Sep 2017 - 09:00 am CHMP positive opinion to include RE-CIRCUIT® data for atrial fibrillation patients undergoing catheter ablation in Pradaxa® Summary of Product Characteristics
15. Sep 2017 - 01:45 pm Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO®
12. Sep 2017 - 12:59 pm Jardiance® reduced risk of cardiovascular death in people with type 2 diabetes and established CV disease* independent of background blood sugar control
11. Sep 2017 - 02:00 pm Safety and efficacy results from the INJOURNEYTM  trial investigating OFEV® (nintedanib) with add-on pirfenidone provide new data to support nintedanib’s key role in IPF
07. Sep 2017 - 02:00 pm Boehringer Ingelheim is initiating Phase IIa study for the development of a new treatment for diabetic retinopathy – a leading cause of vision-loss
07. Sep 2017 - 02:00 pm Boehringer Ingelheim and Gubra collaborate to develop next generation obesity treatments 
29. Aug 2017 - 03:15 pm Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm), a biosimilar to Humira®, for the treatment of multiple chronic inflammatory diseases
27. Aug 2017 - 02:55 pm Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement
24. Aug 2017 - 02:00 pm Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH 
21. Aug 2017 - 09:00 am Boehringer Ingelheim: advancing anticoagulation care with new data at ESC Congress 2017
03. Aug 2017 - 10:00 am Next generation of veterinary scientists gathers at National Institutes of Health for National Veterinary Scholars Symposium
02. Aug 2017 - 10:00 am Boehringer Ingelheim achieves good growth in the first half of 2017
27. Jul 2017 - 03:00 pm Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA® 
24. Jul 2017 - 09:00 am People with idiopathic pulmonary fibrosis (IPF) reveal high burden of disease in new survey
11. Jul 2017 - 12:00 pm Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations
03. Jul 2017 - 03:30 pm Jardiance® (empagliflozin) analysis reinforces established safety profile
29. Jun 2017 - 08:30 am 'More than Systemic Sclerosis: The Inside Story' – patients reveal the unseen impact of lung fibrosis
21. Jun 2017 - 10:30 am New data reveal high rates of stroke history  in asymptomatic atrial fibrillation patients
14. Jun 2017 - 03:00 pm Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA® 
12. Jun 2017 - 02:00 pm Empagliflozin (Jardiance®) to be studied in chronic kidney disease
08. Jun 2017 - 12:45 pm Boehringer Ingelheim builds Digital Lab “BI X” with focus on innovative digital solutions in healthcare
05. Jun 2017 - 09:00 am Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017
24. May 2017 - 01:00 pm IPF patients treated with OFEV® (nintedanib) versus placebo were twice as likely to have improved or stable lung function1
23. May 2017 - 02:00 pm ATS 2017 Spiriva® Respimat® improves breathing for people with asthma regardless of BMI or allergic status
16. May 2017 - 01:00 pm Boehringer Ingelheim strengthens early science portfolio through comprehensive multifaceted partnership with Peking University 
16. May 2017 - 05:00 am Boehringer Ingelheim Inaugurates World-Class Biopharmaceutical Manufacturing Facility in China 
10. May 2017 - 11:00 am Boehringer Ingelheim Phase II trial now enrolling patients with the kidney disease Lupus Nephritis
05. Apr 2017 - 01:00 pm Boehringer Ingelheim: A New World Leader in Animal Health
05. Apr 2017 - 10:30 am Successful financial year 2016 for Boehringer Ingelheim
30. Mar 2017 - 02:00 pm Novozymes and Boehringer Ingelheim announce Strategic Collaboration in Probiotics for Poultry Hatcheries
20. Mar 2017 - 11:30 am Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases
19. Mar 2017 - 04:00 pm Uninterrupted Pradaxa® Showed Less Major Bleeding than Warfarin in Atrial Fibrillation Patients Undergoing Catheter Ablation
17. Mar 2017 - 01:00 pm First dedicated outcome trials of empagliflozin in chronic heart failure initiated
02. Mar 2017 - 02:00 pm Boehringer Ingelheim expands collaboration with Vanderbilt University to tackle some of the most difficult-to-treat cancers 
02. Mar 2017 - 09:00 am Boehringer Ingelheim sponsors the new building of the Research Institute of Molecular Pathology in Vienna with EUR 52 million 
28. Feb 2017 - 08:00 am New global survey results show:  2 out of 3 patients said they were involved in the decision-making process about the most appropriate treatment in IPF
28. Feb 2017 - 08:00 am Giotrif® (afatinib) Becomes First Second-Generation ErbB Family Blocker Approved for Lung Cancer in China
16. Feb 2017 - 02:30 pm US FDA Expands Approval of Tiotropium Respimat® for Maintenance Treatment of Asthma in Children 
15. Feb 2017 - 02:00 pm Boehringer Ingelheim and Weill Cornell Medicine announce new collaboration to discover next generation COPD treatments
09. Feb 2017 - 02:27 pm Afatinib to be evaluated in combination with PD-1 inhibitor pembrolizumab in new trial for patients with squamous cell carcinoma of the lung 
26. Jan 2017 - 02:00 pm Jardiance® (empagliflozin) becomes first type 2 diabetes medicine in the EU to include cardiovascular death reduction data in label 
18. Jan 2017 - 03:00 pm Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review
02. Jan 2017 - 07:00 am Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017   
16. Dec 2016 - 02:45 pm CHMP adopts a positive opinion acknowledging that Jardiance® reduces the risk of CV death
13. Dec 2016 - 02:00 pm Proven and reliable efficacy: 4 Billion Pigs Protected against M. hyo, PCV 2 and PRRS with vaccines from Boehringer Ingelheim Animal Health 
07. Dec 2016 - 03:00 pm Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease
07. Dec 2016 - 02:25 pm Clinically meaningful data for oral nintedanib in mesothelioma presented at World Conference on Lung Cancer 
05. Dec 2016 - 05:00 pm U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
05. Dec 2016 - 09:00 am New Data Show High Therapy Persistence with Pradaxa® (dabigatran etexilate) in NVAF Patients
28. Nov 2016 - 02:00 pm Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss 
22. Nov 2016 - 03:00 pm Glyxambi® (empagliflozin/linagliptin) approved for adults with type 2 diabetes in the European Union
16. Nov 2016 - 04:30 pm Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin®
16. Nov 2016 - 02:50 pm Boehringer Ingelheim welcomes central role of LAMA/LABA therapy within 2017 GOLD Strategy for COPD 
16. Nov 2016 - 09:45 am Updated Phase III Results Reinforce Safety and Efficacy of Praxbind® (idarucizumab) in Urgent Situations
14. Nov 2016 - 11:00 am New analysis from the IntroDia® survey reveals how people with type 2 diabetes are informed of their diagnosis 
14. Nov 2016 - 09:00 am Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline 
11. Nov 2016 - 12:00 pm Patient enrolment completed for RE-DUAL PCI™ study assessing dabigatran in atrial fibrillation patients after PCI with stenting
08. Nov 2016 - 09:30 am New European study highlights differing priorities in physician’s therapy goals when treating advanced lung cancer patients
26. Oct 2016 - 04:00 pm Most successful animal health vaccine of all time reaches milestone of two billion pigs being protected
26. Oct 2016 - 02:00 pm Boehringer Ingelheim’s adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study
21. Oct 2016 - 10:00 am Three projects win 2016 European PRRS Research Award sponsored by Boehringer Ingelheim Animal Health
18. Oct 2016 - 06:00 pm Boehringer Ingelheim joins The Leukemia & Lymphoma Society in groundbreaking precision medicine approach to treating acute myeloid leukemia 
13. Oct 2016 - 10:00 am New real-world analysis reports lower risk of major bleeding with dabigatran compared to rivaroxaban in stroke prevention
13. Oct 2016 - 08:00 am Boehringer Ingelheim announces agreement with Ceva Santé Animale for the sale of certain Merial assets
09. Oct 2016 - 08:15 am Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016
09. Oct 2016 - 08:15 am Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016
30. Sep 2016 - 08:01 am Boehringer Ingelheim returns development and commercial rights of olmutinib to Hanmi Pharmaceutical
29. Sep 2016 - 02:00 pm Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies
28. Sep 2016 - 02:00 pm BOEHRINGER INGELHEIM BOOSTS IMMUNE-ONCOLOGY PIPELINE THROUGH COLLABORATION WITH VIRATHERAPEUTICS 
26. Sep 2016 - 10:00 am Preventing disease: One billion pigs vaccinated with Ingelvac PRRS MLV®
20. Sep 2016 - 01:00 pm  New survey reveals 9 out of 10 patients with IPF were happy with the way their doctor told them about their IPF diagnosis
16. Sep 2016 - 02:30 pm Glyxambi® (empagliflozin/linagliptin) approval recommended by CHMP for adults with type 2 diabetes in the European Union
09. Sep 2016 - 12:30 pm Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
08. Sep 2016 - 08:00 am New analysis showed dose adjustment of Giotrif® (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer 
07. Sep 2016 - 03:30 pm New long-term data demonstrates continued safety and beneficial effect of OFEV® (nintedanib) for patients with IPF
06. Sep 2016 - 03:44 pm Tiotropium Respimat® improved lung function in children with asthma aged 6-17 and is well-tolerated compared to placebo in children aged 1-171–5
05. Sep 2016 - 04:30 pm Simple blood test combined with exacerbation history may help to identify when to add ICS to COPD treatment
05. Sep 2016 - 04:30 pm New Data: Spiolto® Respimat® significantly improves exercise capacity in people with COPD
01. Sep 2016 - 03:00 pm Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational BiTE immuno-oncology drug for multiple myeloma
29. Aug 2016 - 05:45 pm Latest data on dabigatran etexilate safety and effectiveness profile show low rates of bleeding and stroke in NVAF patients in routine clinical care
29. Aug 2016 - 08:30 am Saniona and Boehringer Ingelheim sign collaboration agreement in schizophrenia
15. Aug 2016 - 02:00 pm Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind® usage in clinical practice
03. Aug 2016 - 10:00 am Boehringer Ingelheim: Growth in all core businesses
25. Jul 2016 - 03:00 pm Boehringer Ingelheim stops LUX-Head & Neck 2 and 4 trials following pre-planned analysis from independent Data Monitoring Committee 
21. Jul 2016 - 09:00 am CZ Veterinaria and Boehringer Ingelheim Animal Health announce cooperation to bring innovative sow vaccine Entericolix® to the European market
20. Jul 2016 - 10:00 am The European Stroke Organisation and Boehringer Ingelheim launch the “Angels Initiative”, a unique healthcare initiative to improve acute stroke care across Europe
14. Jul 2016 - 11:00 am Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines 
13. Jul 2016 - 02:00 pm Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
07. Jul 2016 - 03:00 pm Marina von Keyserlingk and Daniel Weary win first Ruminant Well-being Award
04. Jul 2016 - 01:00 pm Gaia Novarino wins Boehringer Ingelheim’s FENS Award 2016 for Exceptional Research in Neuroscience 
30. Jun 2016 - 10:00 am INMARKTM now enrolling: first study to evaluate the effect of OFEV® (nintedanib) on biomarkers reflecting the underlying fibrotic process in IPF patients 
27. Jun 2016 - 10:00 am New analysis of INPULSIS® trials demonstrates efficacy of OFEV® (nintedanib) across a range of IPF patients using broader diagnostic criteria
27. Jun 2016 - 07:00 am Sanofi and Boehringer Ingelheim have reached definitive agreements to swap Sanofi’s Animal Health and Boehringer Ingelheim’s Consumer Healthcare businesses
14. Jun 2016 - 05:00 pm Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
12. Jun 2016 - 07:00 pm New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
11. Jun 2016 - 05:00 pm New study results show Trajenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
11. Jun 2016 - 09:00 am Results of Phase III study of volasertib for the treatment of acute myeloid leukaemia presented at European Hematology Association Annual Meeting
10. Jun 2016 - 01:00 pm Simone Menne – new Member of the Board of Managing Directors of Boehringer Ingelheim/Responsible for Corporate Board Division Finance
07. Jun 2016 - 04:00 pm Boehringer Ingelheim and Harvard scientists establish a research alliance to find novel treatments for severe fibrotic diseases
05. Jun 2016 - 02:00 pm New data on olmutinib (BI 1482694) presented at ASCO 2016 underscores clinical potential of Boehringer Ingelheim’s next generation lung cancer compound 
02. Jun 2016 - 02:00 pm Boehringer Ingelheim launches ambitious ELUXA trial programme to broadly investigate promising lung cancer compound olmutinib
31. May 2016 - 10:00 am Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis
26. May 2016 - 12:00 pm 3 out of 4 people with symptomatic asthma report reduced productivity at work 
25. May 2016 - 09:00 am Boehringer Ingelheim increases access to the medication for the treatment of HIV/Aids
24. May 2016 - 05:00 pm IL-23 inhibitor risankizumab induces remission in Phase II study in patients with moderate-to-severe Crohn’s disease 
23. May 2016 - 10:00 am Boehringer Ingelheim and  BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing
23. May 2016 - 08:45 am Pooled data analysis of placebo-controlled trials confirms improvement in quality of life within 4 weeks of using oral bisacodyl/sodium picosulfate
17. May 2016 - 10:30 am South Korea is first to approve next generation lung cancer treatment olmutinib (BI 1482694 / HM61713)
16. May 2016 - 02:00 pm New Presentations at ATS 2016 Reinforce OFEV® (nintedanib) Efficacy, Safety and Tolerability Across Broad Range of Patients with IPF
11. May 2016 - 12:00 pm Pradaxa®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain
11. May 2016 - 09:00 am Nine out of 10 AF patients are concerned about stroke and many want to be part of OAC treatment decisions, new international survey shows
10. May 2016 - 02:00 pm New claim for use of Metacam®20mg/ml in sheep simultaneously granted in Australia, Canada and New Zealand
09. May 2016 - 09:00 am LUME-Meso trial enrols first patient: Boehringer Ingelheim’s new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma
21. Apr 2016 - 10:00 am Boehringer Ingelheim initiates clinical evaluation of novel compound for chronic kidney disease
19. Apr 2016 - 11:00 am Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure
19. Apr 2016 - 10:30 am Boehringer Ingelheim has a successful 2015 financial year
18. Apr 2016 - 11:02 am Major mental health project aims to uncover root causes of social withdrawal 
18. Apr 2016 - 09:00 am New concept and design of boehringer-ingelheim.com: Corporate website as central web hub with customer-focused news and stories 
13. Apr 2016 - 09:00 am Head-to-head study demonstrating Giotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology
08. Apr 2016 - 08:00 am The Lancet Respiratory Medicine: New analysis shows only minority of COPD patients may benefit from inhaled corticosteroids  
07. Apr 2016 - 09:00 am Giotrif® (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung   
04. Apr 2016 - 09:00 am Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations
30. Mar 2016 - 10:00 am Boehringer Ingelheim Venture Fund invests in Amal Therapeutics to develop novel therapeutic colorectal cancer vaccine
23. Mar 2016 - 10:31 am Boehringer Ingelheim launches RE-COVERY DVT/PE™:  global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)
15. Mar 2016 - 11:00 am 2016 European PRRS Research Award: Boehringer Ingelheim Animal Health calls for submissions until July 1st
08. Mar 2016 - 09:00 am New Analyses: Adding SPIRIVA® Respimat®  Effective for Uncontrolled Asthma – Regardless of Allergy Subtype
07. Mar 2016 - 02:00 pm AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
01. Mar 2016 - 10:00 am Boehringer Ingelheim Animal Health supports independent PCV2 research with total of € 650,000
29. Feb 2016 - 02:15 pm  European Committee for Medicinal Products for Human Use recommends approval of Giotrif® (afatinib) for advanced squamous cell cancer of the lung   
29. Feb 2016 - 09:00 am New survey gives voice to people living with a rare and devastating lung disease: “When I think of IPF I think of breathlessness”
25. Feb 2016 - 02:00 pm  New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations 
10. Feb 2016 - 11:51 am The European Society of Cardiology announces winners of innovative cardiovascular research grant programme
04. Feb 2016 - 11:00 am SPIRIVA® RESPIMAT® Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
27. Jan 2016 - 12:01 pm Boehringer Ingelheim’s Giotrif® / Gilotrif® (afatinib) demonstrated superiority to Iressa® (gefitinib) in reducing the risk of disease progression
22. Jan 2016 - 12:07 pm European Commission confirms CMDh recommendation: Benefit/risk profiles of ambroxol and bromhexine products are favorable
15. Jan 2016 - 12:22 pm World Association for Buiatrics and Boehringer Ingelheim Animal Health announce “Ruminant Well-being Award”
13. Jan 2016 - 01:14 pm Boehringer Ingelheim and Arena Pharmaceuticals Collaborate to Advance Research in Schizophrenia
22. Dec 2015 - 12:21 pm Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site
21. Dec 2015 - 12:41 pm 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
18. Dec 2015 - 02:50 pm Strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress
15. Dec 2015 - 12:56 pm Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap
14. Dec 2015 - 04:35 pm Initiation of first multinational study to evaluate safety of OFEV® (nintedanib) with add-on of pirfenidone in patients with IPF
08. Dec 2015 - 11:15 am New Phase III study of nintedanib in people with systemic sclerosis and lung fibrosis
02. Dec 2015 - 02:15 pm Boehringer Ingelheim and MD Anderson join forces
30. Nov 2015 - 10:40 am Experts call for improved EGFR mutation testing
26. Nov 2015 - 04:30 pm Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
17. Nov 2015 - 12:15 pm Time is of the essence for millions living with ‘neglected’ lung disease
16. Nov 2015 - 01:00 pm Boehringer Ingelheim named one of the most innovative companies worldwide
13. Nov 2015 - 02:30 pm New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)
11. Nov 2015 - 03:00 pm Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years to accelerate the discovery of next generation medical breakthroughs
10. Nov 2015 - 04:30 pm Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® in Routine Clinical Care
10. Nov 2015 - 03:15 pm Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
10. Nov 2015 - 02:58 pm Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab
10. Nov 2015 - 11:30 am Boehringer Ingelheim Presents New idarucizumab (Praxbind®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran
09. Nov 2015 - 12:00 pm New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
06. Nov 2015 - 12:45 pm Change in Board of Managing Directors to ensure continuity and focus on the future
06. Nov 2015 - 12:15 pm EMPA-REG OUTCOME®: Top-line renal data to be presented during American Society of Nephrology (ASN) Kidney Week 2015
03. Nov 2015 - 04:32 pm Boehringer Ingelheim initiates pivotal programme for novel third-generation EGFR targeting lung cancer compound
28. Oct 2015 - 09:45 pm CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto® Respimat®
28. Oct 2015 - 04:39 pm Boehringer Ingelheim’s Biosimilar Candidate Demonstrated Pharmacokinetic Bioequivalence to Adalimumab
19. Oct 2015 - 03:45 pm FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate)
15. Oct 2015 - 10:45 pm Boehringer Ingelheim Animal Health presents its first live web congress on Bovine Viral Diarrhoea
12. Oct 2015 - 04:30 am Boehringer Ingelheim and Philogen partner on AML
09. Oct 2015 - 09:45 pm Boehringer Ingelheim Animal Health announces winners of the 2015 European PRRS Research Award
08. Oct 2015 - 12:00 pm Boehringer Ingelheim’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study
08. Oct 2015 - 10:48 am Delayed IPF diagnosis negatively impacts patients by delaying treatment according to global survey of pulmonologists
29. Sep 2015 - 12:00 pm New data demonstrate sustained long-term efficacy of OFEV®* on slowing disease progression and safety in patients with IPF
28. Sep 2015 - 04:23 pm COPD: New data support role of Spiolto® Respimat® as 1st-line maintenance therapy and show superiority over LABA/ICS
27. Sep 2015 - 02:40 pm VARGATEF® plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compared to docetaxel alone
27. Sep 2015 - 11:39 am ECC 2015: GIOTRIF® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status
25. Sep 2015 - 12:00 pm CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)
25. Sep 2015 - 08:00 am Results from European survey in NSCLC
22. Sep 2015 - 03:48 pm Boehringer Ingelheim Animal Health launches two new swine vaccines in Europe
21. Sep 2015 - 04:15 pm Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD
21. Sep 2015 - 03:40 pm ERS 2015: Landmark year for Boehringer Ingelheim’s respiratory portfolio - new data for COPD, IPF and asthma treatments
17. Sep 2015 - 04:45 pm Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial
16. Sep 2015 - 04:27 pm Asthma: U.S. FDA approves new indication for SPIRIVA® Respimat®
15. Sep 2015 - 01:23 pm EASD: Additional Evidence Showed ABASAGLAR (insulin glargine) Provided Safety and Efficacy Similar to Lantus
15. Sep 2015 - 08:49 am Type 2 diabetes: International survey shows quality of patient-physician conversation at diagnosis linked to better patient outcomes
08. Sep 2015 - 05:35 pm More than 50% of patients struggle with lung cancer
07. Sep 2015 - 09:00 am European Medicines Agency (EMA) approves the use of Ingelvac CircoFLEX® during pregnancy and lactation in sows
01. Sep 2015 - 06:33 am Boehringer Ingelheim licenses Vectron Biosolutions’ expression technology platform
29. Aug 2015 - 03:36 pm ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim
28. Aug 2015 - 09:41 am Expansion of the Boehringer Ingelheim Board of Managing Directors / Andreas Neumann responsible for Human Resources
25. Aug 2015 - 09:45 am FDA and EMA accept GIOTRIF® in squamous submission
20. Aug 2015 - 03:43 pm Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events
17. Aug 2015 - 10:00 am New data show Spiolto® Respimat® provides meaningful quality of life improvements in COPD
12. Aug 2015 - 06:10 am Boehringer Ingelheim and Circuit Therapeutics announce new collaboration to discover novel medicines for obesity
04. Aug 2015 - 06:29 am Boehringer Ingelheim experiences slight growth in local currency terms in the first half of 2015
28. Jul 2015 - 02:22 pm Boehringer Ingelheim and Hanmi developing EGFR TKI
24. Jul 2015 - 04:18 pm MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke
15. Jul 2015 - 08:21 am Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)
02. Jul 2015 - 12:04 pm New advance in COPD maintenance treatment, Spiolto® Respimat®, approved in first European countries
01. Jul 2015 - 06:21 am Boehringer Ingelheim Animal Health: 2015 European PRRS Research Award open for submissions until July 31st
22. Jun 2015 - 11:30 am Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study
16. Jun 2015 - 03:24 pm New publication in The Lancet describes effective reversal of Pradaxa® in healthy volunteers
08. Jun 2015 - 02:30 pm Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA
08. Jun 2015 - 09:15 am Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care
06. Jun 2015 - 03:30 pm Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) in patients with previously treated advanced squamous cell carcinoma of the lung
03. Jun 2015 - 03:17 pm NICE recommends VARGATEF® (nintedanib*) in combination with docetaxel as an option for patients with non-small cell lung cancer of adenocarcinoma histology within its licensed indication
03. Jun 2015 - 09:34 am Respimat® success story: Boehringer Ingelheim invests EUR 72 million in production capacity in Ingelheim
31. May 2015 - 12:27 pm ASCO 2015: Superior OS for afatinib vs erlotinib
28. May 2015 - 11:30 am Type 2 diabetes: Synjardy® (empagliflozin/metformin hydrochloride) approved in the European Union
28. May 2015 - 10:18 am Boehringer Ingelheim and researchers at The University of Michigan collaborate to study mechanisms of diabetic nephropathy in Pima Indians
27. May 2015 - 10:56 am Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association’s® 75th Scientific Sessions
26. May 2015 - 05:59 pm FDA approves Boehringer Ingelheim’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD
21. May 2015 - 06:12 pm Eureka Therapeutics Inc. and Boehringer Ingelheim Announce a Collaboration to Identify Next Generation Antibodies for Cancer Treatment
20. May 2015 - 06:28 pm New data show benefit of tiotropium/olodaterol Respimat® from the start of COPD maintenance therapy
20. May 2015 - 03:12 pm Boehringer Ingelheim welcomes the update of the ATS/ERS/JRS/ALAT 2011 evidence based guidelines for treatment of idiopathic pulmonary fibrosis (IPF), suggesting nintedanib* for the treatment of IPF.
18. May 2015 - 06:57 pm Boehringer Ingelheim acquires Pharmaxis’ phase 1 anti-inflammatory drug candidate
18. May 2015 - 03:08 pm Data Comparison shows onset of action of oral hyoscine butylbromide already as early as 15 minutes
18. May 2015 - 12:40 pm New data and analyses confirm the efficacy and safety of OFEV® (nintedanib*) for the treatment of IPF beyond 52 weeks and for distinct subgroups
14. May 2015 - 03:03 pm Boehringer Ingelheim showcases expanding presence in lung cancer at ASCO 2015 with new data including presentation of afatinib* overall survival results for squamous cell carcinoma of the lung
13. May 2015 - 07:05 pm First patient enrolled in dabigatran study comparing anticoagulation strategies during AF ablation
22. Apr 2015 - 07:24 pm 2014: Boehringer Ingelheim positioned for future growth with product launches
17. Apr 2015 - 02:59 pm New international survey of lung cancer oncologists highlights underutilization of personalized treatments
13. Apr 2015 - 08:00 am Hydra Biosciences and Boehringer Ingelheim Enter Research Collaboration Focused on Renal Diseases and Disorders
30. Mar 2015 - 01:30 am Type 2 diabetes: CHMP recommends empagliflozin/metformin hydrochloride for approval in the European Union
20. Mar 2015 - 02:10 am Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study
16. Mar 2015 - 07:54 am Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment
12. Mar 2015 - 07:59 am EFSD and Boehringer Ingelheim: celebrating joint research and support Academic Diabetes Research in Europe
03. Mar 2015 - 08:21 am Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada
02. Mar 2015 - 08:44 am Innovative protection against Bovine Viral Diarrhea: Boehringer Ingelheim launches Bovela® in Europe
24. Feb 2015 - 02:55 pm Boehringer Ingelheim Animal Health continues support of independent PCV2 research
27. Jan 2015 - 09:00 am New large-scale study to investigate effect of tiotropium + olodaterol Respimat® on exacerbations in COPD
19. Jan 2015 - 09:50 am OFEV® (nintedanib*) approved in the EU for the treatment of IPF
15. Jan 2015 - 10:21 am Boehringer Ingelheim and Sanofi enter into a strategic contract manufacturing alliance to produce biopharmaceuticals
15. Jan 2015 - 10:08 am 35 partners from industry and academia to join European research initiative for the prevention of Alzheimer’s dementia
14. Jan 2015 - 12:00 pm Boehringer Ingelheim and Vanderbilt join forces to develop new Ras inhibitors for cancer treatment
13. Jan 2015 - 11:05 am Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeutic areas
12. Jan 2015 - 02:50 pm The Lancet Oncology publishes Phase III data showing Giotrif® (afatinib*) significantly extended overall survival of lung cancer patients with the most common EGFR mutation over chemotherapy
22. Dec 2014 - 02:45 pm New vaccine against Bovine Viral Diarrhea: Boehringer Ingelheim receives European marketing authorization for Bovela®
15. Dec 2014 - 12:06 pm First trial of a novel oral anticoagulant starts in prevention of recurrent stroke due to a blood clot of undetermined source
12. Dec 2014 - 12:18 pm LUX-Breast 1 and LUX-Breast 3 data presented
09. Dec 2014 - 12:26 pm New data show specific antidote idarucizumab* reverses dabigatran-induced anticoagulation also in elderly and renally impaired volunteers
04. Dec 2014 - 12:44 pm Investing in the development of innovative active ingredients: Boehringer Ingelheim opens a new technology centre in Biberach
27. Nov 2014 - 12:36 pm Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy
21. Nov 2014 - 12:53 pm Nintedanib* receives positive CHMP opinion in European Union for the treatment of IPF
19. Nov 2014 - 05:36 pm Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin
19. Nov 2014 - 01:29 pm New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans
14. Nov 2014 - 11:30 am Boehringer Ingelheim "Runs" to support vital programs in Diabetes and Stroke
07. Nov 2014 - 02:36 pm New subgroup analysis shows Asian non-small cell lung cancer patients with most common EGFR mutation (del19) lived significantly longer with first-line GIOTRIF® (afatinib*) compared to chemotherapy
07. Nov 2014 - 11:53 am GIOTRIF® Asian EGFR M+ NSCLC subgroup analysis
04. Nov 2014 - 09:15 am Asthma: Boehringer Ingelheim announces U.S. FDA filing acceptance of NDA for Spiriva® Respimat® in asthma
03. Nov 2014 - 09:37 am FDA Medicare study in 134,000 atrial fibrillation patients confirms positive safety profile and effectiveness of Pradaxa® in general practice
29. Oct 2014 - 10:10 am Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries
27. Oct 2014 - 10:23 am Vargatef® (nintedanib) approved in the EU for NSCLC
21. Oct 2014 - 02:30 pm Boehringer Ingelheim initiates global Phase III study investigating nintedanib* in patients with colorectal cancer refractory to standard treatments
21. Oct 2014 - 10:43 am LUME-COLON 1 global phase III study initiated
20. Oct 2014 - 12:13 pm Winners of the 2014 European PRRS Research Award announced
16. Oct 2014 - 12:32 pm Boehringer Ingelheim’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis
30. Sep 2014 - 01:15 am Boehringer Ingelheim invests €100 million: Expanded Respimat® production in Dortmund
27. Sep 2014 - 06:06 pm Afatinib vs Erlotinib head-to-head trial results
27. Sep 2014 - 02:08 pm Afatinib results from LUX Head and Neck 1 trial
27. Sep 2014 - 12:49 pm Boehringer Ingelheim’s afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer
27. Sep 2014 - 12:26 pm Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung
26. Sep 2014 - 06:19 pm Nintedanib* receives positive CHMP opinion for second-line treatment of patients with adenocarcinoma of the lung
18. Sep 2014 - 06:28 pm Boehringer Ingelheim and CureVac collaboration
16. Sep 2014 - 06:45 pm Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study
10. Sep 2014 - 06:56 pm European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe
09. Sep 2014 - 07:28 pm Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50th EASD Annual Meeting
09. Sep 2014 - 07:17 pm Nintedanib slowed disease progression in IPF independent of patients’ lung function impairment at baseline
08. Sep 2014 - 12:06 pm European Respiratory Society International Congress 2014
08. Sep 2014 - 02:00 am "European Respiratory Society International Congress 2014 TONADO™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC* in COPD"
08. Sep 2014 - 01:45 am Asthma: new indication for Spiriva® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care 
02. Sep 2014 - 07:49 am ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa® on kidney function over time compared to warfarin
01. Sep 2014 - 05:15 pm Boehringer Ingelheim to present comprehensive data supporting broad respiratory portfolio in COPD, asthma and IPF at ERS 2014
01. Sep 2014 - 08:11 am Extensive experience in clinical practice and expanding research programme support use of Pradaxa® for clot prevention
01. Sep 2014 - 07:53 am Boehringer Ingelheim Animal Health sees freshly mixed swine vaccines as its way forward
25. Aug 2014 - 08:22 am New Pradaxa® data to be presented at the ESC Congress 2014
25. Aug 2014 - 08:00 am New Pradaxa® data to be presented at the ESC Congress 2014
22. Aug 2014 - 08:42 am Boehringer Ingelheim Animal Health celebrates 20 years of PRRS control and innovation
19. Aug 2014 - 09:02 am First patients enrolled in study to evaluate dabigatran etexilate after PCI with stenting
11. Aug 2014 - 10:01 am First half year 2014: Boehringer Ingelheim meets challenges
04. Aug 2014 - 10:06 am Boehringer Ingelheim receives two FDA approvals
23. Jul 2014 - 04:40 pm Pradaxa® (dabigatran etexilate) Video Statement
23. Jul 2014 - 10:29 am Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed
22. Jul 2014 - 03:23 pm Boehringer Ingelheim Establishes a Research Alliance with the University of Toronto
16. Jul 2014 - 11:18 am Boehringer Ingelheim’s investigational therapy nintedanib* receives the first FDA breakthrough therapy designation in IPF
08. Jul 2014 - 10:37 am Volasertib phase II study results
07. Jul 2014 - 10:53 am Judit Makara wins Boehringer Ingelheim’s FENS Award 2014 for Exceptional Research in Neuroscience
06. Jul 2014 - 11:45 am New GIOTRIF® data published in The Lancet Oncology
30. Jun 2014 - 11:11 am U.S. FDA grants Breakthrough Therapy Designation to Pradaxa® (dabigatran etexilate) specific investigational antidote
30. Jun 2014 - 08:00 am U.S. FDA grants Breakthrough Therapy Designation to Pradaxa® (dabigatran etexilate) specific investigational antidote
27. Jun 2014 - 12:04 pm CHMP Recommends Lilly and Boehringer Ingelheim’s New Insulin Glargine Product for Approval in the European Union
20. Jun 2014 - 12:32 pm Boehringer Ingelheim Statement on Hepatitis C drug development
20. Jun 2014 - 12:27 pm New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation
16. Jun 2014 - 01:00 pm Type 2 Diabetes: Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials
16. Jun 2014 - 12:42 pm New AML survey in five European countries
15. Jun 2014 - 01:34 pm Type 2 Diabetes: Physicians worldwide agree early conversations are crucial in the management of condition
14. Jun 2014 - 02:23 pm Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar in Safety and Efficacy to Lantus®
10. Jun 2014 - 10:33 am Diabetes: Boehringer Ingelheim and Eli Lilly and Company Alliance to have 43 Presentations Featured at the American Diabetes Association’s 74th Scientific Sessions®
06. Jun 2014 - 11:28 am Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism
05. Jun 2014 - 01:08 pm EMA accepts marketing authorisation application for nintedanib in IPF
03. Jun 2014 - 04:26 pm Boehringer Ingelheim Announces Successful Resolution of FDA Warning Letter
02. Jun 2014 - 04:36 pm New GIOTRIF® data shows over 1 year survival 
30. May 2014 - 06:24 pm ASCO 2014: New phase III data in lung cancer
28. May 2014 - 05:05 pm Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate) litigation
23. May 2014 - 11:30 am Type 2 Diabetes: European Commission approves Jardiance® (empagliflozin)
22. May 2014 - 12:12 pm Antidote for rapid reversal of Pradaxa® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients
21. May 2014 - 12:30 pm ATS 2014 COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva®) alone
19. May 2014 - 01:15 pm Additional results from post-hoc analysis underline effectiveness of SPIRIVA®
18. May 2014 - 01:15 pm IPF Phase III results published in NEJM show nintedanib slows disease progression
16. May 2014 - 01:06 pm ASCO 2013: New Phase III data reveal targeted treatment with afatinib* or with nintedanib* improves progression-free survival in patients with advanced NSCLC
15. May 2014 - 02:49 pm As the benefits and safety of Pradaxa® (dabigatran etexilate) are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa to help more patients
15. May 2014 - 01:34 pm GIOTRIF® demonstrates significant OS benefit
12. May 2014 - 03:17 pm Boehringer Ingelheim will make detailed clinical trial data available to the scientific community
07. May 2014 - 03:27 pm New registry data highlight substantial global differences in stroke prevention for patients with an irregular heart beat
07. May 2014 - 03:25 pm New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients
06. May 2014 - 12:00 pm Type 2 Diabetes Research: Connexios Life Sciences and Boehringer Ingelheim Enter Agreement for Novel AMPK Activators
30. Apr 2014 - 06:24 pm Boehringer Ingelheim to present highly anticipated Phase III data in IPF and COPD at ATS International Conference
30. Apr 2014 - 08:41 am Boehringer Ingelheim Animal Health announces the 2014 European PRRS Research Award
25. Apr 2014 - 08:46 am Positive CHMP opinion for Pradaxa® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots
24. Apr 2014 - 06:47 pm Hydra Biosciences and Boehringer Ingelheim announce worldwide collaboration to develop small-molecule inhibitors for the treatment of central nervous system diseases and disorders
17. Apr 2014 - 06:57 pm Volasertib granted orphan drug designation in EU
16. Apr 2014 - 09:13 am Boehringer Ingelheim receives “Facility of the Year Award” for Equipment Innovation in biopharmaceutical manufacturing
15. Apr 2014 - 09:31 am Boehringer Ingelheim pleased with 2013 financial year
09. Apr 2014 - 09:42 am Boehringer Ingelheim Animal Health supports PCV2 research projects with 500,000 euro
08. Apr 2014 - 09:52 am FDA approves Pradaxa® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)
21. Mar 2014 - 10:30 am Type 2 Diabetes: CHMP recommends empagliflozin* for approval
13. Mar 2014 - 10:57 am Type 2 Diabetes: New poll of more than 700 Latin American physicians provides insights into complexity and challenges
11. Mar 2014 - 11:17 am 10,000 patients with atrial fibrillation now enrolled in innovative GLORIA™-AF Registry
06. Mar 2014 - 11:49 am Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
06. Mar 2014 - 11:38 am Boehringer Ingelheim Announces Phase 3 SVR12 Results in HCV/HIV Co-Infected Patients Treated with Faldaprevir
01. Mar 2014 - 06:00 pm "AAAAI 2014 ASTHMA: New Phase III data show tiotropium* Respimat® effective across asthma severities"
17. Feb 2014 - 10:25 am Boehringer Ingelheim Receives East Bay Innovation Award
12. Jan 2014 - 10:38 am GIOTRIF® data published in The Lancet Oncology
07. Jan 2014 - 11:15 am Crystal Bioscience and Boehringer Ingelheim Announce Multiple Target Antibody Discovery Collaboration
20. Dec 2013 - 11:25 am Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product
18. Dec 2013 - 11:37 am Circuit Therapeutics and Boehringer Ingelheim announce signature of a research partnership agreement to discover new approaches to treating psychiatric disorders
17. Dec 2013 - 11:46 am New data on safety and efficacy of Pradaxa® in treatment of acute deep vein thrombosis and pulmonary embolism
16. Dec 2013 - 12:14 pm Hepatitis C: Phase III data show Boehringer Ingelheim’s faldaprevir* is effective even in patients with common drug-resistant viral variant
10. Dec 2013 - 06:27 pm New data analyses show consistent efficacy and safety profile of Pradaxa® in broad range of patients with acute deep vein thrombosis or pulmonary embolism*
03. Dec 2013 - 03:18 am New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin in adults newly diagnosed with Type 2 Diabetes
02. Dec 2013 - 03:33 am Largest global survey investigating early Type 2 Diabetes conversations launched by Boehringer Ingelheim and Eli Lilly and Company in partnership with the International Diabetes Federation
26. Nov 2013 - 04:07 am Hepatitis C: Boehringer Ingelheim’s faldaprevir granted accelerated assessment from European Medicines Agency
25. Nov 2013 - 09:32 am Pradaxa® (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY®
19. Nov 2013 - 10:13 am New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years
19. Nov 2013 - 09:57 am Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa® (dabigatran etexilate) in expanded patient populations
18. Nov 2013 - 10:43 am First human data show promise of Boehringer Ingelheim's specific antidote for immediate, complete and sustained reversal of Pradaxa®-induced anticoagulation
15. Nov 2013 - 11:00 am Boehringer Ingelheim goes "Blue" in supporting World Diabetes Day activities
13. Nov 2013 - 11:15 am Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat® to the treatment of asthma in adults aged 18 years and over
12. Nov 2013 - 11:56 am Boehringer Ingelheim supports victims of typhoon Haiyan in the Philippines
12. Nov 2013 - 11:25 am New efficacy and safety data for Pradaxa® (dabigatran etexilate) to be announced at American Heart Association's Scientific Sessions 2013
11. Nov 2013 - 12:05 pm Micardis® crosses 50 million patient-years of experience on 15th anniversary
07. Nov 2013 - 12:20 pm New data presented at AASD further demonstrate benefits of Trajenta® (linagliptin) with efficacy and safety in specific patient populations
06. Nov 2013 - 12:38 pm New survey in four major Asian countries reveals complexity of managing Type 2 Diabetes is currently underestimated
02. Nov 2013 - 06:28 pm Phase III data show Boehringer Ingelheim's faldaprevir* was highly effective in a broad range of patients with genotype-1 hepatitis C
02. Nov 2013 - 01:15 pm Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising Phase II data
29. Oct 2013 - 06:53 pm New data show Striverdi® (olodaterol)* Respimat® improves exercise tolerance in patients with moderate to very severe COPD
28. Oct 2013 - 11:18 am Global Lung Cancer Coalition to identify patient challenges and improve support strategies in partnership with Boehringer Ingelheim
28. Oct 2013 - 08:00 am Lung Cancer: We're Listening collaboration
27. Oct 2013 - 07:33 pm New efficacy and safety data adds to evidence supporting treatment with afatinib*(GIOTRIF®) in Asian and non-Asian lung cancer patients
18. Oct 2013 - 07:45 pm New once-daily Striverdi* (olodaterol) Respimat® gains approval in first EU countries
14. Oct 2013 - 08:36 am Boehringer Ingelheim submits nintedanib, a novel oncology compound, for European approval
08. Oct 2013 - 11:20 am Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial
07. Oct 2013 - 11:49 am Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin
07. Oct 2013 - 11:45 am Ben Venue Laboratories, Inc. to Cease Production
30. Sep 2013 - 12:01 pm Nintedanib extended survival in 2nd line NSCLC
26. Sep 2013 - 12:28 pm Boehringer Ingelheim significantly expands its production footprint in China
25. Sep 2013 - 12:36 pm GIOTRIF® (afatinib) approved in Europe for patients with EGFR mutation positive lung cancer
24. Sep 2013 - 06:51 pm Data presented at EASD support safety profile of Trajenta® (linagliptin) in broad range of adults with Type 2 Diabetes
24. Sep 2013 - 06:30 pm Pooled analysis data showed improvements in glycaemic parameters, body weight and blood pressure with investigational agent empagliflozin in adults with Type 2 Diabetes
23. Sep 2013 - 02:25 pm New poll highlights treatment priorities of European primary care physicians when managing Type 2 Diabetes
19. Sep 2013 - 07:09 pm Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests
17. Sep 2013 - 07:41 pm Boehringer Ingelheim and Eli Lilly and Company present efficacy and safety data on linagliptin and investigational compound, empagliflozin in various diabetes subpopulations
17. Sep 2013 - 07:20 pm Volasertib FDA Breakthrough Therapy designation
10. Sep 2013 - 01:24 pm Boehringer Ingelheim broadens efforts for interferon-free hepatitis C treatments through clinical collaboration with Presidio Pharmaceuticals
09. Sep 2013 - 08:30 pm Landmark TIOSPIRTM trial reinforces importance of SPIRIVA® in both available formulations as the world's leading maintenance therapy for chronic obstructive pulmonary disease (COPD)
09. Sep 2013 - 02:00 pm ERS Congress 2013 Phase III results: Once daily olodaterol* Respimat® provides effective and sustained improvements in lung function in patients with COPD
09. Sep 2013 - 01:30 pm ERS Congress 2013 New Phase III data presented for first time demonstrate: tiotropium* Respimat® significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS† treatment
03. Sep 2013 - 08:52 pm Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases
03. Sep 2013 - 08:00 am Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases
02. Sep 2013 - 01:17 pm Boehringer Ingelheim to present highly anticipated data from landmark TIOSPIR™ trial, and their respiratory pipeline products in COPD, asthma, IPF and lung cancer at ERS 2013
02. Sep 2013 - 09:20 am New treatment for cats with chronic kidney disease: Boehringer Ingelheim launches Semintra®
26. Aug 2013 - 09:34 am ESC Congress 2013: New data provide evidence for the positive safety and efficacy profile of Pradaxa® in various atrial fibrillation patient populations
16. Aug 2013 - 10:26 am Boehringer Ingelheim takes a further step to establish Animal Health business in Asia
15. Aug 2013 - 06:25 pm Boehringer Ingelheim announces full patient enrolment for two of its pivotal Phase III interferon-free hepatitis C clinical trials
15. Aug 2013 - 10:55 am Phase III safety and efficacy data of Trajenta® (linagliptin) in elderly people with Type 2 Diabetes published in The Lancet
14. Aug 2013 - 06:41 pm First half year 2013: Boehringer Ingelheim remains on growth path
01. Aug 2013 - 01:11 pm Afatinib* shows benefits for EGFR mutation positive non-small cell lung cancer patients across various efficacy endpoints
31. Jul 2013 - 10:26 am First patient enrolled in new cardiovascular and renal outcomes trial for linagliptin in Type 2 Diabetes
26. Jul 2013 - 10:40 am Afatinib receives positive CHMP opinion in NSCLC
17. Jul 2013 - 11:12 am Boehringer Ingelheim and EFSD announce first recipients of diabetes research funding
16. Jul 2013 - 11:40 am Benefits of Pradaxa® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure
16. Jul 2013 - 11:24 am Healthrageous, United BioSource and Boehringer Ingelheim launch SMART digital diabetes Study
15. Jul 2013 - 11:57 am U.S. FDA approves Gilotrif™ (afatinib)* as first-line treatment for lung cancer patients with EGFR mutations
10. Jul 2013 - 12:16 pm Boehringer Ingelheim and Ashoka Changemakers Announce Winners of Transforming Health Systems Competition
08. Jul 2013 - 12:28 pm Eli Lilly and Company and Boehringer Ingelheim announce regulatory submission for new insulin glargine biosimilar product
25. Jun 2013 - 05:18 pm Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials presented at ADA
24. Jun 2013 - 05:29 pm Application submitted to the European Medicines Agency (EMA) for use of Pradaxa® in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE
22. Jun 2013 - 06:45 pm Phase III data show significant reductions in blood glucose with investigational compound empagliflozin used as monotherapy in adults with Type 2 Diabetes
22. Jun 2013 - 04:07 pm Phase III data show investigational compound empagliflozin reduced blood glucose in adults with Type 2 Diabetes treated with basal insulin
22. Jun 2013 - 03:59 pm Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulphonylurea in adults with Type 2 Diabetes
22. Jun 2013 - 04:13 am Trajenta® (linagliptin): New data on safety and efficacy in Type 2 Diabetes patients with moderate to severe renal impairment
22. Jun 2013 - 03:38 am New efficacy and safety data presented for Trajenta® (linagliptin) in Asians with Type 2 Diabetes
22. Jun 2013 - 03:30 am Study finds investigational compound empagliflozin reduced blood glucose in adults with Type 2 Diabetes and impaired kidney function
17. Jun 2013 - 09:24 am New long-term data reinforce safety profile of Pradaxa® for stroke prevention in AF
13. Jun 2013 - 09:53 am Boehringer Ingelheim’s investigational all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C patients
11. Jun 2013 - 10:09 am Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 34 Presentations in Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association® Scientific Sessions
08. Jun 2013 - 10:27 am Boehringer Ingelheim’s investigational faldaprevir+ achieved viral cure in 88% of treatment-naïve hepatitis C patients in Asia
06. Jun 2013 - 11:00 am Boehringer Ingelheim pioneers biopharmaceuticals move to China
03. Jun 2013 - 11:09 am LUME-Lung 1: Nintedanib* plus chemotherapy extends the life of lung cancer patients with adenocarcinoma
01. Jun 2013 - 06:54 pm Afatinib benefits for EGFR M+ NSCLC patients
01. Jun 2013 - 11:52 am Superiority of afatinib* over comparator chemotherapy for patients with EGFR mutation-positive advanced lung cancer is reinforced by second Phase III study
28. May 2013 - 12:07 pm New European survey highlights ischaemic stroke protection as treatment priority for patients with atrial fibrillation
24. May 2013 - 12:26 pm Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, "Complications Combat"
22. May 2013 - 06:24 pm Boehringer Ingelheim responds to FDA warning letter
22. May 2013 - 12:39 pm Wireless Pill Bottle Wins Healthcare Innovation World Cup
21. May 2013 - 06:30 pm Phase III results: tiotropium* Respimat® effective in symptomatic asthma patients despite at least ICS†/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response
17. May 2013 - 06:56 pm Change in the Board of Managing Directors at Boehringer Ingelheim
16. May 2013 - 07:06 pm ASCO 2013: Presenting new data in lung cancer
16. May 2013 - 12:58 pm ASCO 2013: Boehringer Ingelheim to present highly anticipated new Phase III results for front-runner compounds afatinib* and nintedanib* in first- and second-line NSCLC treatment
16. May 2013 - 07:30 am ASCO 2013: New data from LUX Lung 6 and LUME Lung 2
06. May 2013 - 07:33 pm Boehringer Ingelheim joins Structural Genomics Consortium - for further research into uncurable diseases
25. Apr 2013 - 07:42 pm Boehringer Ingelheim Announces a Strong 2012 Performance in China
24. Apr 2013 - 11:41 am Boehringer Ingelheim consistently continues growth phase in financial year 2012
23. Apr 2013 - 12:18 pm "Boehringer Ingelheim announces results from one of its HCV Phase III trials: Investigational compound faldaprevir+ shows high viral cure and early treatment success in treatment-naïve patients with genotype-1 hepatitis C"
02. Apr 2013 - 12:35 pm Innovative treatment for canine epilepsy: European approval granted for Boehringer Ingelheim’s Pexion®
26. Mar 2013 - 11:17 am FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)
26. Mar 2013 - 08:36 am Boehringer Ingelheim and Eli Lilly and Company announce acceptance of European marketing authorisation application for investigational Type 2 Diabetes treatment empagliflozin*
24. Mar 2013 - 10:08 am New Pradaxa® data to be presented during the American College of Cardiology’s 63rd Annual Scientific Session
19. Mar 2013 - 11:52 am Boehringer Ingelheim and Lilly initiate MARLINA-T2D™ clinical trial to evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and albuminuria
11. Mar 2013 - 01:41 pm Pharmaco-invasive strategy including Metalyse® delivers comparable clinical outcomes to primary PCI for STEMI patients who could not undergo primary PCI within one hour from first medical contact
11. Mar 2013 - 12:06 pm American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education with focus on China in 2013
04. Mar 2013 - 01:54 pm Boehringer Ingelheim announces interim results from a Phase III trial in HIV patients co-infected with chronic hepatitis C
28. Feb 2013 - 07:06 pm Rare disease day: Initiation of POLO-AML-2 trial
25. Feb 2013 - 07:28 pm Healthcare Innovation World Cup: Call for Breakthrough Ideas to Tackle Diabetes
23. Feb 2013 - 06:15 pm Phase III results: tiotropium* Respimat® is effective in symptomatic asthma patients irrespective of their allergic status
21. Feb 2013 - 06:38 pm New findings from two studies support substantial benefit of Pradaxa® for prevention of recurrent deep vein thrombosis and pulmonary embolism
14. Feb 2013 - 06:56 pm Preventing disease: One billion pigs vaccinated with Ingelvac CircoFLEX®
30. Jan 2013 - 07:45 pm FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD
23. Jan 2013 - 08:06 pm Boehringer Ingelheim and Ashoka Changemakers Launch Competition to Find Business Models that Transform Health Systems
17. Jan 2013 - 08:41 pm Boehringer Ingelheim and the EFSD call for grant applications in diabetes research
17. Jan 2013 - 08:23 pm Boehringer Ingelheim enrols first patients in pivotal Phase III interferon-free hepatitis C trial programme
16. Jan 2013 - 08:54 pm FDA grants priority review for Afatinib in NSCLC
07. Jan 2013 - 09:37 am Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin
07. Jan 2013 - 09:21 am Lilly reassumes sole worldwide development and commercialization rights for novel basal insulin analog
11. Dec 2012 - 06:25 pm Boehringer Ingelheim discontinues Phase II trial in patients with artificial heart valves
10. Dec 2012 - 07:36 pm Phase III study of volasertib in AML initiated
10. Dec 2012 - 07:19 pm Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin
05. Dec 2012 - 08:03 pm Boehringer Ingelheim and Apexigen sign manufacturing agreement for process development and early stage clinical supply
05. Dec 2012 - 07:50 pm New Pradaxa® safety and efficacy data to be featured at ‘Best of ASH’ session
02. Dec 2012 - 07:23 pm Lilly and Boehringer Ingelheim Present Health Outcomes Data for Investigational Novel Basal Insulin Analogue
14. Nov 2012 - 08:07 am Run for diabetes: Boehringer Ingelheim supports ‘Life for a Child’ programme on World Diabetes Day
13. Nov 2012 - 08:43 am Boehringer Ingelheim and BaroFold Announce Strategic Agreement on PreEMT™ High Pressure Protein Refolding Technology
12. Nov 2012 - 08:56 am Boehringer Ingelheim enters strategic collaboration agreement to support Molecular Partner’s proprietary pipeline with clinical supply of DARPin® molecules
10. Nov 2012 - 10:16 am Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase IIb study including patients with advanced liver disease
08. Nov 2012 - 09:43 am Recruitment complete for Trajenta® (linagliptin) cardiovascular outcome study in patients with Type 2 Diabetes
08. Nov 2012 - 09:17 am RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa® for stroke prevention in AF
06. Nov 2012 - 06:45 pm Safety and efficacy of Pradaxa® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement
05. Nov 2012 - 11:10 am Pradaxa® - Development of antidote may expand range of methods to reverse anticoagulant effect during emergency situations
05. Nov 2012 - 10:54 am FDA and EMA reaffirm important health benefits and safety of Pradaxa® (dabigatran etexilate) for patients with atrial fibrillation
31. Oct 2012 - 11:59 am Wealth of worldwide evidence on Pradaxa® including first clinical data on long-term efficacy and safety of a novel oral anticoagulant to be presented at AHA Scientific Sessions
26. Oct 2012 - 06:00 pm The Respimat® success story: Boehringer Ingelheim doubles its production capacity
26. Oct 2012 - 12:30 pm European approval granted for Trajenta® (linagliptin) tablets as add-on therapy to insulin in adults with Type 2 Diabetes
11. Oct 2012 - 06:42 pm NICE recommends treatment with alteplase is started as early as possible, within 4.5 hours of onset of ischaemic stroke symptoms
11. Oct 2012 - 06:30 pm Boehringer Ingelheim congratulates Nobel Prize winner Prof. Brian Kobilka
04. Oct 2012 - 07:02 pm Final Phase IIb interferon-free hepatitis C data from Boehringer Ingelheim to be presented at AASLD
02. Oct 2012 - 07:44 pm Analyses presented at EASD support Trajenta® (linagliptin) as effective and well-tolerated for patients with type 2 diabetes with different background therapies
25. Jul 2012 - 01:03 pm Jentadueto® (linagliptin/metformin hydrochloride) tablets receive approval for the treatment of adults with Type 2 Diabetes in Europe
23. Jul 2012 - 11:00 pm Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L and the somatotaxin portfolio to treat inflammation
25. Jun 2012 - 02:30 pm No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa® (dabigatran etexilate) compared to enoxaparin for VTE prevention after orthopaedic surgery 
25. Jun 2012 - 02:30 pm No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa® (dabigatran etexilate) compared to enoxaparin for VTE prevention after orthopaedic surgery 
18. Jun 2012 - 03:09 pm Boehringer Ingelheim BioXcellence: Distinctive brand for the biopharmaceutical contract manufacturing business
09. Jun 2012 - 12:46 pm New data demonstrate sustained glucose reduction and weight loss up to 90 weeks
21. May 2012 - 01:17 pm Boehringer Ingelheim’s once-daily bronchodilator olodaterol* successfully completes Phase II clinical trial program in COPD
29. Apr 2012 - 01:33 pm Switching to TWYNSTA® allows patients with uncontrolled hypertension on monotherapy to rapidly reach their blood pressure goals
10. Oct 2009 - 04:54 pm Mirapexin®/Sifrol® Information